Overview

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Vortioxetine